The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://www.share-talk.com/top-twenty-the-stocks-of-the-year-for-2021/#gs.pgkkaa
Happy New Year everyone!
Posted by FiveprimeOAS over on Stockwits. Seems to know what he's talking about or does a decent job of faking it
I have zero doubts of the efficacy of Foralumab. Antibodies do one thing, they bind to their cognate antigen. This one binds to CD3. Blocking CD3 phosphorylation of ITAMS has a singular, very predictable effect: it will significantly reduce inflammation through the induction of regulatory T cells. I am however on pins and needles regarding the means of administration. The very second that nasal administration of a monoclonal antibody therapy is shown to be effective, a new era of immunotherapies will begin. I can't explain how exciting this is as a researcher.
Thanks Olds, they sound legit. Lol
Did GC put a timescale on getting some more independent broker valuations of the company?
From my memory someone asked that question during call and he agreed and said it's in hand, or something along those lines.
Shakin, TILS is applying for a standard listing on the main market. Only premium listings are eligible for FTSE inclusion and incur even greater costs. Didn't know myself so had a bit of a look around:
https://www.valuethemarkets.com/2018/02/26/aim-listing-vs-standard-listing-main-market-whats-difference/
The Mother of all bounces of $2 hopefully lbc
100% you will not be locked out during move to main market.
Just waiting for the company to let us know when the date is. Fingers crossed for an update this week!
LW - no new shares are being issued and Ticker stays the same so technically we shouldn't see any difference.
For me it also signals the ambition of the company and where they see the rightful place of TILS. I'd expect this along with pending trial results to start some upward momentum but who knows.
Rightly or wrongly I thought main market listing entails greater regulatory requirements which opens it up to investors and institutions who wouldn't touch aim.
I welcome the move too and trust the BOD know what they're doing.
DGOC would be a good case study for the move from AIM to main market, they did it earlier this year.
I believe we still need to give formal notice and publish a prospectus etc.
Good lord Shiraz, not sure I can handle another demerger!!
John, he may well be referring to the fact that TZLS501 inhibits IL6 but also depletes existing levels of IL6. Double whammy so to speak!
A bit of random Googling lead me to this site where you can obtain Foralumab. In the text it mentions it can be used to prevent skin xenograft rejection in mice which I'd never heard.
Doubt the revenue from mouse skin grafts is that big so glad we're going after Chrohns and Alzheimer's :-)
https://www.creativebiolabs.net/Anti-Human-CD3-epsilon-Therapeutic-Antibody-foralumab-13775.htm?gclid=EAIaIQobChMIyIz0_M6A7QIVFdZ3Ch18UgYCEAMYAiAAEgJ1G_D_BwE
Morning everyone.
If they were to initiate the move away from AIM on Monday that would take us to 14th Dec at earliest for trading on main market. What's the chance they're trying to synchronise Brazil results with trading on MM?
Bigger pool of investors and less potential manipulation?
With the main market move the company needs to issue a detailed Prospectus and not just a quick RNS to cover the more stringent regulations.
Due soon and the perfect opportunity for a bit of gentle ramping from the BOD. At the very least we'll probably see GC on another Proactive video. Suit please this time GC, we're going main market after all!
Probably lucky LSE chat was down, wouldn't want my panic recorded for posterity!
Spinn,
Posted a bit out of frustration tonight as thought we would now focus on Tiziana as we're all post Record date. Should have just let things be as I'm all Accustem'd out!
Apologies, don't know the answer to your question but either way it's been and gone.
May drop in over the weekend if anything interesting comes up otherwise see you all Monday.
Cheers
There's no uncertainty.
On Monday Tiziana is trading as Tiziana and not Tiziana/Accustem no matter where you buy or sell them.
Probably should not have used ex-entitlement in my previous post but it is in all but name. Record dates have passed but can't be officially classed as Ex on Nasdaq because shares have not been delivered to ADR holders.
The updates LW referred to are only regarding formal listing of Accustem on LSE as that will be the catalyst for ADR delivery. That date is not set but has no bearing on who has or will receive Accustem shares on both sides of the Atlantic. That time has come and gone.